Merck Wins FDA Approval for First Oral PCSK9 Inhibitor Cholesterol Pill

Merck announced on Thursday that the U.S. Food and Drug Administration has approved Lipfendra, marking a historic first for cholesterol treatment. The pill represents the inaugural oral PCSK9 inhibitor to reach the American market, giving patients a new option beyond injectable medications. This approval strengthens Merck’s portfolio as the pharmaceutical giant prepares for the eventual patent expiration of Keytruda, its blockbuster cancer treatment, which faces potential biosimilar competition starting in 2028.

The new medication, also known as enlicitide, targets patients diagnosed with hypercholesterolemia, a condition characterized by elevated levels of LDL cholesterol in the bloodstream. Medical professionals commonly refer to LDL as the “bad” cholesterol because it contributes to plaque accumulation in arterial walls. According to the American Heart Association, approximately one in four adults in the United States currently struggle with high LDL cholesterol levels, making this a critical public health concern affecting millions of Americans.

Lipfendra operates through a different mechanism than traditional cholesterol medications by targeting the PCSK9 protein, which regulates cholesterol levels in the body. In contrast, older oral statins work by blocking a specific enzyme that the liver uses to produce cholesterol. This distinction gives physicians another tool in their treatment arsenal, particularly for patients who may not respond adequately to statin therapy alone or who require additional cholesterol reduction beyond what statins can provide.

Injectable Market Dominance Faces New Competition

The cholesterol-lowering drug landscape has been dominated by injectable PCSK9 inhibitors for years, with Amgen’s Repatha and the joint offering from Regeneron and Sanofi called Praluent leading the market. These injectable treatments require patients to administer shots, often creating barriers to adherence and patient preference. Merck’s oral formulation eliminates the need for injections, potentially improving patient compliance and expanding the treatment population willing to use PCSK9 inhibitor therapy.

The pharmaceutical company’s once-daily pill format offers convenience that could reshape treatment patterns for cardiovascular disease prevention. Patients who previously hesitated to use injectable medications now have access to the same class of powerful cholesterol-lowering therapy in tablet form. This accessibility factor may prove crucial in addressing the substantial population of Americans living with elevated cholesterol levels who remain undertreated or struggle with existing treatment regimens.

Scotiabank analyst Louise Chen previously projected that Lipfendra could achieve “peak sales potential of tens of billions of dollars,” underscoring the commercial opportunity Merck has captured with this approval. The substantial revenue forecast reflects both the large patient population affected by high cholesterol and the potential preference for oral medication over injectable alternatives. Such projections also highlight the strategic importance of this approval for Merck’s future revenue streams.

Clinical Evidence Supports Regulatory Decision

The FDA based its decision on evidence from two late-stage clinical trials that demonstrated significant LDL cholesterol reduction across diverse patient populations. The studies enrolled patients with varying cholesterol profiles, including those diagnosed with familial hypercholesterolemia, a genetic condition causing severely elevated cholesterol levels from birth. Trial participants also included individuals already taking statin medications who needed additional cholesterol lowering to reach their therapeutic goals.

Results from these pivotal trials showed that the once-daily pill significantly reduced LDL cholesterol levels across this broad patient spectrum. The consistent efficacy across different patient types strengthens the drug’s potential utility in clinical practice, where physicians encounter patients with varying degrees of cholesterol elevation and different underlying causes. The robust clinical data package satisfied the FDA’s stringent requirements for demonstrating both safety and effectiveness in lowering cardiovascular risk markers.

The FDA designated the drug under the National Priority Voucher program, an initiative overseen by the FDA commissioner to accelerate review timelines for medications deemed critical to public health or national security. This designation recognizes the urgent need for improved cholesterol treatment options given the widespread prevalence of cardiovascular disease in America. The expedited pathway allowed Merck to bring this therapy to patients faster than standard review processes would permit.

Strategic Importance Beyond Keytruda

For Merck, this approval carries significant strategic weight beyond the immediate patient benefits. The company faces a looming challenge as Keytruda, its leading cancer immunotherapy, approaches patent cliff dates beginning in 2028. Once patent protections expire, biosimilar manufacturers will introduce less expensive versions of the drug, eroding Merck’s market share and revenue from this crucial product. Diversifying the product portfolio with high-potential therapies like Lipfendra helps offset this anticipated revenue decline.

The cholesterol medication market represents one of the largest pharmaceutical segments globally, with millions of patients requiring long-term daily therapy to manage cardiovascular risk. Unlike cancer treatments that may be used for defined treatment courses, cholesterol medications typically remain part of a patient’s daily regimen for years or decades. This creates a stable, recurring revenue stream that can help stabilize Merck’s financial performance as other products face patent expiration and competitive pressure.

Market Access and Patient Impact

Lipfendra now becomes the first oral option in a drug class that previously required patients to self-inject medication, typically every two weeks or monthly depending on the specific product. This fundamental shift in administration route addresses a common barrier cited by patients and physicians when considering PCSK9 inhibitor therapy. Many patients express reluctance about injectable medications due to discomfort, inconvenience, or needle anxiety, limiting the reach of these highly effective treatments.

The approval positions Merck to capture market share not only from existing injectable PCSK9 inhibitors but potentially from patients currently managed on statins alone who might benefit from additional cholesterol lowering. Physicians may find it easier to prescribe and patients easier to accept an oral medication that can be added to existing statin therapy without introducing injections into the treatment regimen. The commercial launch timeline and pricing strategy will prove critical factors in determining how quickly Lipfendra gains traction in this competitive therapeutic area.

Healthcare providers treating cardiovascular disease now have an expanded toolkit for managing one of America’s most prevalent health challenges. With one in four adults affected by high LDL cholesterol, the introduction of a convenient oral PCSK9 inhibitor addresses a substantial unmet medical need. The medication’s arrival signals potential improvements in cholesterol control rates across the population, particularly among patients who previously declined or discontinued injectable therapy options.